Downregulation of p21waf/cip-1 mediates apoptosis of human hepatocellular carcinoma cells in response to interferon-γ

Experimental Cell Research

Volumn 282, Issue 2, 2003, Pages 78-89

  Detjen, Katharina M ^a   Murphy, Derek ^a   Welzel, Martina ^a   Farwig, Katrin ^a   Wiedenmann, Bertram ^a   Rosewicz, Stefan ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Medizinische Klinik Mit Schwerpunkt Kardiologie   (Germany)

Author keywords

Apoptosis; Cyclin D; Hepatocellular carcinoma; Interferon ; p21cip waf

Indexed keywords

CASPASE 3; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; DNA FRAGMENT; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 1BETA CONVERTING ENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHOTRANSFERASE; PROTEIN P21; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARCINOMA CELL; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL FUNCTION; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ASSAY; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0037440476     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00011-3     Document Type: Article

References (52)

1. Schafer D.F., Sorrell M.F. Hepatocellular carcinoma. Lancet. 353:1999;1253-1257.
2. Chen P.J., Chen D.S., Lai M.Y., Chang M.H., Huang G.T., Yang P.M., Sheu J.C., Lee S.C., Hsu H.C., Sung J.L. Clonal origin of recurrent hepatocellular carcinomas. Gastroenterology. 96:1989;527-529.
3. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin. Liver Dis. 19:1999;235-242.
4. Kalvakolanu D.V. Interferons and cell growth control. Histol. Histopathol. 15:2000;523-537.
5. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:1997;749-795.
6. Maheshwari R.K., Srikantan V., Bhartiya D., Kleinman H.K., Grant D.S. Differential effects of interferon gamma and alpha on in vitro model of angiogenesis. J. Cell Physiol. 146:1991;164-169.
7. Bromberg J.F., Horvath C.M., Wen Z., Schreiber R.D., Darnell J.E. Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA. 93:1996;7673-7678.
8. Meraz M.A., White J.M., Sheehan K.C., Bach E.A., Rodig S.J., Dighe A.S., Kaplan D.H., Riley J.K., Greenlund A.C., Campbell D., Carver-Moore K., DuBois R.N., Clark R., Aguet M., Schreiber R.D. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 84:1996;431-442.
9. Platanias L.C., Fish E.N. Signaling pathways activated by interferons. Exp. Hematol. 27:1999;1583-1592.
10. Bromberg J., Darnell J.E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 19:2000;2468-2473.
11. Grander D., Einhorn S. Interferon and malignant disease - how does it work and why doesn't it always? Acta Oncol. 37:1998;331-338.
12. Kaplan D.H., Shankaran V., Dighe A.S., Stockert E., Aguet M., Old L.J., Schreiber R.D. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc.Natl. Acad. Sci. USA. 95:1998;7556-7561.
13. Rodig S., Kaplan D., Shankaran V., Old L., Schreiber R.D. Signaling and signaling dysfunction through the interferon gamma receptor. Eur. Cytokine Netw. 9:1998;49-53.
14. Maier J.A., Morelli D., Balsari A. The differential response to interferon gamma by normal and transformed endothelial cells. Biochem. Biophys. Res. Commun. 214:1995;582-588.
15. Sangfelt O., Erickson S., Grander D. Mechanisms of interferon-induced cell cycle arrest. Front. Biosci. 5:2000;D479-D487.
16. Tamura T., Ueda S., Yoshida M., Matsuzaki M., Mohri H., Okubo T. Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem. Biophys. Res. Commun. 229:1996;21-26.
17. Dighe A.S., Richards E., Old L.J., Schreiber R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1:1994;447-456.
18. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
19. Kano A., Haruyama T., Akaike T., Watanabe Y. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem. Biophys. Res. Commun. 257:1999;672-677.
20. Lotem J., Sachs L. Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds. Proc. Natl. Acad. Sci. USA. 95:1998;4601-4606.
21. Xaus J., Cardo M., Valledor A.F., Soler C., Lloberas J., Celada A. Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity. 11:1999;103-113.
22. Drexler H.G., Zaborski M., Quentmeier H. Interferon-gamma induced proliferation of human myeloid leukaemia cell lines. Br. J. Haematol. 98:1997;699-710.
23. Harvat B.L., Jetten A.M. Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ. 7:1996;289-300.
24. Detjen K.M., Farwig K., Welzel M., Wiedenmann B., Rosewicz S. Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut. 49:2001;251-262.
25. Smiley S.T., Reers M., Mottola-Hartshorn C., Lin M., Chen A., Smith T.W., Steele G.D. Jr., Chen L.B. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA. 88:1991;3671-3675.
26. Matsushime H., Quelle D.E., Shurtleff S.A., Shibuya M., Sherr C.J., Kato J.Y. D-Type cyclin-dependent kinase activity in mammalian cells. Mol. Cell Biol. 14:1994;2066-2076.
27. Murphy D., Detjen K.M., Welzel M., Wiedenmann B., Rosewicz S. Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology. 33:2001;346-356.
28. Elbashir S.M., Harborth J., Weber K., Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 26:2002;199-213.
29. Kano A., Watanabe Y., Takeda N., Aizawa S., Akaike T. Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. J. Biochem. (Tokyo). 121:1997;677-683.
30. Jiang S., Song M.J., Shin E.C., Lee M.O., Kim S.J., Park J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology. 29:1999;101-110.
31. Lamboley C., Bringuier A.F., Feldmann G. Apoptotic behaviour of hepatic and extra-hepatic tumor cell lines differs after Fas stimulation. Cell Mol. Biol. (Noisy.-le-grand). 46:2000;13-28.
32. Horiuchi M., Yamada H., Akishita M., Ito M., Tamura K., Dzau V.J. Interferon regulatory factors regulate interleukin-1 beta-converting enzyme expression and apoptosis in vascular smooth muscle cells. Hypertension. 33:1999;162-166.
33. Dotto G.P. p21(WAF1/Cip1) more than a break to the cell cycle? Biochim. Biophys. Acta. 1471:2000;M43-M56.
34. Gorospe M., Wang X., Guyton K.Z., Holbrook N.J. Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol. Cell Biol. 16:1996;6654-6660.
35. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18:1999;1223-1234.
36. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., Villa A., Marchisio P.C., Altieri D.C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1:1999;461-466.
37. Suzuki A., Ito T., Kawano H., Hayashida M., Hayasaki Y., Tsutomi Y., Akahane K., Nakano T., Miura M., Shiraki K. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene. 19:2000;1346-1353.
38. Xu S.Q., El Deiry W.S. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem. Biophys. Res. Commun. 269:2000;179-190.
39. Gorospe M., Cirielli C., Wang X., Seth P., Capogrossi M.C., Holbrook N.J. p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene. 14:1997;929-935.
40. Waldman T., Lengauer C., Kinzler K.W., Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381:1996;713-716.
41. Soldner F., Weller M., Haid S., Beinroth S., Miller S.W., Wullner U., Davis R.E., Dichgans J., Klockgether T., Schulz J.B. MPP+ inhibits proliferation of PC12 cells by a p21 (WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). Exp. Cell Res. 250:1999;75-85.
42. Poluha W., Poluha D.K., Chang B., Crosbie N.E., Schonhoff C.M., Kilpatrick D.L., Ross A.H. The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. Mol. Cell Biol. 16:1996;1335-1341.
43. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 272:1996;719-722.
44. Ouchi T., Lee S.W., Ouchi M., Aaronson S.A., Horvath C.M. Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes. Proc. Natl. Acad. Sci. USA. 97:2000;5208-5213.
45. Horvai A.E., Xu L., Korzus E., Brard G., Kalafus D., Mullen T.M., Rose D.W., Rosenfeld M.G., Glass C.K. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA. 94:1997;1074-1079.
46. Bromberg J.F. Activation of STAT proteins and growth control. Bioessays. 23:2001;161-169.
47. Klausen P., Pedersen L., Jurlander J., Baumann H. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 19:2000;3675-3683.
48. Kordula T., Bugno M., Goldstein J., Travis J. Activation of signal transducer and activator of transcription-3 (Stat3) expression by interferon-gamma and interleukin-6 in hepatoma cells. Biochem. Biophys. Res. Commun. 216:1995;999-1005.
49. Urashima M., Teoh G., Chauhan D., Hoshi Y., Ogata A., Treon S.P., Schlossman R.L., Anderson K.C. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood. 90:1997;279-289.
50. Dey A., Li W. Cell cycle-independent induction of D1 and D2 cyclin expression, but not cyclin-Cdk complex formation or Rb phosphorylation, by IFNgamma in macrophages. Biochim. Biophys. Acta. 1497:2000;135-147.
51. Sherr C.J. The Pezcoller lecture Cancer cell cycles revisited . Cancer Res. 60:2000;3689-3695.
52. Sibinga N.E., Wang H., Perrella M.A., Endege W.O., Patterson C., Yoshizumi M., Haber E., Lee M.E. Interferon-gamma-mediated inhibition of cyclin A gene transcription is independent of individual cis-acting elements in the cyclin A promoter. J. Biol. Chem. 274:1999;12139-12146.